Clinical trials located in

Ostrava

Ostrava city is located in Czechia. Currently, 20 clinical trials are being conducted in this city.

Ostrava, located in the northeastern Czech Republic, is the country’s third-largest city. Historically known as a coal mining and heavy industry hub, it has undergone significant transformation into a vibrant cultural and educational center. The city boasts unique industrial heritage sites, including the Lower Vítkovice area, a former steel plant turned cultural space. Ostrava is also home to the Stodolní Street, famous for its lively nightlife with numerous bars and clubs. The city’s strategic position near the Polish and Slovak borders adds to its multicultural ambiance.

  • CT-EU-00120106

    Study of Elafibranor in the treatment of adult patients with Primary Biliary Cholangitis (PBC)

    The clinical trial is aimed at adult patients with confirmed primary cholangitis (PBC). Patients with this condition have an inadequate response or intolerance to ursodeoxycholic acid (UDCA), a drug used to treat PBC.

    Primary cholangitis is a disease that slowly progresses and leads to damage to the bile ducts in the liver. This causes a build-up of bile acids, which further damages the liver. As the disease progresses, scarring of the liver may develop (cirrhosis). PBC is also associated with numerous symptoms, such as itching and fatigue, and may lead to the need for a liver transplant.

    The study evaluates the effectiveness and safety of a drug called elafibranor at a dose of 80 mg daily. The study will compare elafibranor with a placebo, an inactive substance administered for control purposes. The main goal of the study is to test the effectiveness of elafibranor. The safety of long-term use of this medicine and its effect on symptoms such as itching and fatigue will also be checked.

    • Elafibranor
  • To evaluate a combination of 3 different drugs versus 2 other drugs in the treatment of patients with melanoma

    This study compares two different approaches to treating advanced melanoma, a type of skin cancer that has spread to other parts of the body. This study is specifically aimed at patients with a gene mutation called BRAF who have previously received treatment with drugs such as nivolumab or pembrolizumab.

    One therapeutic approach involves taking three study drugs: pembrolizumab administered intravenously every 3 weeks, along with encorafenib and binimetinib taken orally daily at home. The second approach involves taking two study drugs: ipilimumab and nivolumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatments will last for approximately 2 years, but there is no time limit for treatment with encorafenib and binimetinib.

    The research team will closely monitor the patients’ health during regular clinic visits to see how they are responding to treatment. The main goal is to determine which treatment method is more effective in shrinking or eliminating melanoma tumors.

    • Nivolumab
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Study on Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

    Patients with Primary Biliary Cholangitis (PBC) can participate in a clinical trial involving the drug Seladelpar, available in 5 mg and 10 mg capsule forms. The trial aims to evaluate the long-term safety and tolerability of this drug, also known by the code MBX-8025.

    Seladelpar is being tested on a group of approximately 500 patients to determine its long-term tolerability and effectiveness in individuals with PBC. The objective is also to assess the drug’s impact on patient-reported symptoms, such as itching (pruritus).

    The study includes individuals who have previously participated in PBC studies involving seladelpar. Participants will be monitored for 60 months to collect data on potential side effects and laboratory test results.

    The overall goal of the study is to improve the treatment of patients with Primary Biliary Cholangitis by thoroughly investigating the new drug in terms of its safety and efficacy.

    • Seladelpar
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Safety study of tafasitamab with lenalidomide for Diffuse Large B-Cell Lymphoma patients

    In this study, a novel approach to the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) is being investigated. This type of cancer may have either recurred or not responded to previous treatments. The experimental intervention involves the use of two drugs: Tafasitamab, administered intravenously, and Lenalidomide, a oral medication. The study is focused on individuals who have undergone one to three prior treatments and are currently ineligible for intensive chemotherapy or a stem-cell transplant. The study is conducted in an open format, providing transparency regarding the substances being tested. Regular monitoring will be implemented to detect any potential issues and assess the concentration of the medications in participants’ blood.

    • Tafasitamab
    • Lenalidomide
  • Iptacopan’s effect on adult patients with atypical hemolytic uremic syndrome

    This study is conducted to understand if a medicine called iptacopan (also known as LNP023) is safe and effective in treating a disease called Atypical Hemolytic Uremic Syndrome (aHUS) in adults who have never received a type of medication known as a complement inhibitor. Around 50 adults will be given 200 mg of this iptacopan pill twice a day. The doctors will measure how their illness responds by looking at blood tests, kidney health, how often they need to have their blood cleansed by a machine (dialysis), the progression of their kidney illness, and how they feel energetically and about their quality of life. Side effects of taking iptacopan will be recorded for a year.

    • Iptacopan
  • Evaluating effects of pembrolizumab with chemotherapy and radiation for esophageal cancer

    This trial explores the impact of a drug called pembrolizumab on patients with a specific kind of cancer, Esophageal Carcinoma. It compares two treatments. Some patients will receive the standard treatment (chemotherapy and radiation), plus a placebo. Others will receive the standard treatment (chemotherapy and radiation) plus Pembrolizumab. The reason for doing it is to see if Pembrolizumab, when added to normal treatment, can help patients live without their cancer getting worse, or live longer overall. During the trial, patients will either be given pembrolizumab or placebo, as well as one of two chemotherapy combinations and radiation treatment, for about a year.

    • Pembrolizumab
    • levoleucovorin
    • leucovorin
    • 5-Fluorouracil
    • Cisplatin
    • Oxaliplatin
  • Testing the effect of the new drug on Crohn’s Disease

    This study is exploring a new medication for Crohn’s disease, an ailment of the gut. The medication, known as BI 706321, is given alongside another medication called Ustekinumab that is already used to treat Crohn’s. The trial is conducted to see if this combination helps to manage the disease better. Participants will be split into two groups. One group will be given the new medication and the other will receive a placebo, alongside Ustekinumab. Participating in this study will last for 1 year. During this time, participants will have about 13 visits to the clinic. Some visits will involve a colonoscopy where doctors look at the intestine’s condition. Their findings will help doctors understand if the new treatment is working.

    • BI 706321- new potential medication for Crohn’s disease
    • ustekinumab
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    • Mirikizumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing new drugs for lung cancer

    This study is for people with advanced lung cancer diagnosed with the KRAS G12C mutation. The study is separated into two parts: Phase 2 and Phase 3. In Phase 2, Adagrasib will be used, a kind of pill, alone and together with a medicine called Pembrolizumab to see how well it works and how safe it is. In the Phase 3, the study will compare how well Adagrasib and Pembrolizumab work together versus Pembrolizumab alone. The aim is to see how effective this combination is and compare it with the standard care. Side effects and see how the body processes the drug will be also tested.

    • Adagrasib
    • Pembrolizumab
  • Comparing atogepant and topiramate for migraine prevention

    In this study, a comparison is being made between two different medicines aimed at preventing migraines in adults. Migraines manifest as severe headaches on one side of the head, accompanied by symptoms such as nausea, throbbing pain, or sensitivity to light and sound. The two medicines under comparison are named atogepant and topiramate. Atogepant is currently employed for migraine prevention in individuals experiencing migraines from 0 to 14 days per month, and the study seeks to evaluate its potential broader application. Topiramate is already widely utilized for migraine prevention. Participants in this study will be divided into two groups: one group will be administered atogepant, while the other will receive topiramate for a duration of 24 weeks. Following this period, those eligible to continue will all receive atogepant for an additional 52 weeks. The study will assess their progress and monitor any potential side effects.

    • Topiramate
    • Atogepant
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Comparison of new treatment and standard care for lymphoma patients

    A new approach to treating Lymphoma, a type of cancer originating in cells constituting the body’s immune system, is being tested in this trial. Comparison is being made between a new treatment, referred to as MB-CART2019.1, and the presently conventional treatment. The MB-CART2019.1 therapy is designed to target the aberrant B cells responsible for this form of cancer. In the process of creating MB-CART2019.1, cells are extracted from the patient’s own body, modified in the laboratory to combat cancer, and subsequently reintroduced into the patient. Participants in this trial will receive either MB-CART2019.1 or the standard treatment. The standard treatment involves the use of a drug combination (rituximab, gemcitabine, oxaliplatin (R-GemOx) or bendamustine, rituximab (BR) + polatuzumab vedotin). The objective is to assess whether MB-CART2019.1 demonstrates superior efficacy compared to these conventional drugs. Patient progress will be closely monitored for approximately one year to evaluate their well-being.

    • Gemcitabine
    • Polatuzumab vedotin
    • Bendamustine
    • Rituximab
    • Oxaliplatin
    • Rituximab
  • Assessing long-term safety of asciminib therapy in Chronic Myelogenous Leukemia

    This trial serves as a follow-up study for individuals who participated in a previous Novartis-sponsored investigation involving the medication asciminib. The primary objective is to monitor any potential long-term side effects that may arise in individuals who have continued taking Asciminib beyond the initial study. This global study is conducted across numerous hospitals and clinics and is characterized as ‘open-label,’ signifying that participants are aware that they are receiving asciminib. During each visit, the team will assess and record whether participants continue to experience benefits from asciminib.

    • Asciminib
    • Bosutinib
    • Dasatinib
    • Nilotinib
    • Imatinib
  • Mirikizumab’s role in treating active ulcerative colitis

    The study investigates the impact of mirikizumab in adults with moderately to severely active ulcerative colitis. Spanning 36 weeks, the trial evaluates the drug’s effectiveness in controlling symptoms and improving patients’ quality of life.

    • Mirikizumab
  • Study on Ianalumab’s effect on primary immune phrombocytopenia

    This trial is testing Ianalumab against a placebo in patients with a condition called primary immune thrombocytopenia (ITP), a disorder where the body’s immune system mistakenly targets and destroys its own platelets – blood cells that help with clotting and prevent bleeding. The study aims at finding if two different doses of Ianalumab in combination with first-line corticosteroids can efficiently keep the platelet count above a certain level (30 G/L). The study is happening at many different locations and is random and blind, which means neither patients nor doctors know who gets which treatment, to ensure fairness and unbiased results.

    • Ianalumab
  • Evaluating itch relief in liver disease with linerixibat

    The GLISTEN study is a detailed research project exploring the effectiveness of a medication called linerixibat in treating severe itching in people with a liver condition known as Primary Biliary Cholangitis (PBC). In this study, participants are given either linerixibat or a placebo to see which one better reduces itching and improves sleep and overall quality of life. This research is important for finding new ways to help people with PBC who experience discomfort from itching.

    • Linerixibat

See more clinical trials in other cities in Czechia:

.